Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis.

Marzel A, Kusejko K, Weber R, Bruggmann P, Rauch A, Roth JA, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

Open Forum Infect Dis. 2018 May 19;5(5):ofy078. doi: 10.1093/ofid/ofy078. eCollection 2018 May.


Effects of combination approach on harm reduction programs: the Taiwan experience.

Lin T, Chen CH, Chou P.

Harm Reduct J. 2016 Jul 4;13(1):23. doi: 10.1186/s12954-016-0112-3.


Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: System dynamics simulation model.

Atun RA, Lebcir RM, McKee M, Habicht J, Coker RJ.

Health Policy. 2007 May;81(2-3):207-17. Epub 2006 Jul 18.


The role of needle exchange programs in HIV prevention.

Vlahov D, Junge B.

Public Health Rep. 1998 Jun;113 Suppl 1:75-80. Review.


Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.

Todd CS, Nasir A, Stanekzai MR, Fiekert K, Sipsma HL, Vlahov D, Strathdee SA.

Harm Reduct J. 2015 Oct 16;12:22. doi: 10.1186/s12954-015-0056-z.


HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.

Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, Krishna N, Teshale EH, Paz-Bailey G; National HIV Behavioral Surveillance System Study Group.

MMWR Surveill Summ. 2014 Jul 4;63(6):1-51.


Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.

Emmanuelli J, Desenclos JC.

Addiction. 2005 Nov;100(11):1690-700. Erratum in: Addiction. 2006 Apr;101(4):616.


HIV epidemic among drug users in China: 1995-2011.

Wang L, Guo W, Li D, Ding Z, McGoogan JM, Wang N, Wu Z, Wang L; China National HIV/AIDS Surveillance Program.

Addiction. 2015 Jan;110 Suppl 1:20-8. doi: 10.1111/add.12779.


[HIV infection and injecting drug users: The urgency of reinvigorating harm-reduction programmes].

Trujols J, Iraurgi I, Solà I, Ballesteros J, Siñol N, Batlle F, Pérez de Los Cobos J.

Adicciones. 2010;22(2):135-40. Spanish.


Coverage to curb the emerging HIV epidemic among injecting drug users in Pakistan: delivering prevention services where most needed.

Emmanuel F, Fatima M.

Int J Drug Policy. 2008 Apr;19 Suppl 1:S59-64. doi: 10.1016/j.drugpo.2007.12.012. Epub 2008 Feb 20.


The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh.

Guinness L, Vickerman P, Quayyum Z, Foss A, Watts C, Rodericks A, Azim T, Jana S, Kumaranayake L.

Addiction. 2010 Feb;105(2):319-28. doi: 10.1111/j.1360-0443.2009.02755.x. Epub 2009 Nov 18.


Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.

Alistar SS, Owens DK, Brandeau ML.

PLoS Med. 2011 Mar;8(3):e1000423. doi: 10.1371/journal.pmed.1000423. Epub 2011 Mar 1.


HIV among injecting drug users in Europe: increasing trends in the East.

Wiessing L, van de Laar MJ, Donoghoe MC, Guarita B, Klempová D, Griffiths P.

Euro Surveill. 2008 Dec 11;13(50). pii: 19067.


Drug use and HIV/AIDS in China.

Liu Z, Lian Z, Zhao C.

Drug Alcohol Rev. 2006 Mar;25(2):173-5. Review.


"Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001.

Des Jarlais DC, Perlis T, Arasteh K, Hagan H, Milliken J, Braine N, Yancovitz S, Mildvan D, Perlman DC, Maslow C, Friedman SR.

J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):158-66.


Harm reduction, HIV and development.

Deany P, Crofts N.

Dev Bull. 2000 Jun;(52):45-8.


Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.

Nosyk B, Zang X, Min JE, Krebs E, Lima VD, Milloy MJ, Shoveller J, Barrios R, Harrigan PR, Kerr T, Wood E, Montaner JSG.

Lancet HIV. 2017 Jul;4(7):e303-e310. doi: 10.1016/S2352-3018(17)30045-0. Epub 2017 Mar 30.


Drug use among the urban poor in Kolkata: behaviour and environment correlates of low HIV infection.

Panda S, Saha U, Pahari S, Nathan M, Poddar S, Neogi D, Sarkar M, Pal NK, Mahalanabis D.

Natl Med J India. 2002 May-Jun;15(3):128-34.


Supplemental Content

Support Center